4.5 Article

LINC00511 contributes to glioblastoma tumorigenesis and epithelial-mesenchymal transition via LINC00511/miR-524-5p/YB1/ZEB1 positive feedback loop

期刊

JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
卷 24, 期 2, 页码 1474-1487

出版社

WILEY
DOI: 10.1111/jcmm.14829

关键词

epithelial-mesenchymal transition; glioblastoma; LINC00511; tumorigenesis; ZEB1

资金

  1. National Natural Science Foundation of China [81471269, 81472362, 81372709]
  2. Jiangsu Province's Natural Science Foundation [BK20160047]
  3. Jiangsu Province's Key Discipline of Medicine [XK201117]
  4. Jiangsu Province Medical Key Talent [ZDRCB2016002]
  5. Priority Academic Program Development of Jiangsu Higher Education Institution [PAPD]

向作者/读者索取更多资源

Tumour invasion is closely related to the prognosis and recurrence of glioblastoma multiforme and partially attributes to epithelial-mesenchymal transition. Long intergenic non-coding RNA 00511 (LINC00511) plays a pivotal role in tumour; however, the role of LINC00511 in GBM, especially in the epigenetic molecular regulation mechanism of EMT, is still unclear. Here, we found that LINC00511 was up-regulated in GBM tissues and relatively high LINC00511 expression predicted poorer prognosis. Moreover, ectopic LINC00511 enhanced GBM cells proliferation, EMT, migration and invasion, whereas LINC00511 knockdown had the opposite effects. Mechanistically, we confirmed that ZEB1 acted as a transcription factor for LINC00511 in GBM cells. Subsequently, we found that LINC00511 served as a competing endogenous RNA that sponged miR-524-5p to indirectly regulate YB1, whereas, up-regulated YB1 promoted ZEB1 expression, which inversely facilitated LINC00511 expression. Finally, orthotopic xenograft models were performed to further demonstrate the LINC00511 on GBM tumorigenesis. This study demonstrates that a LINC00511/miR-524-5p/YB1/ZEB1 positive feedback loop provides potential therapeutic targets for GBM progression.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据